Home » Roche Taps Psynova to Develop Schizophrenia Companion Diagnostic

Roche Taps Psynova to Develop Schizophrenia Companion Diagnostic

December 3, 2009

Roche is exploiting U.K.-based Psynova Neurotech’s expertise for the development of immunoassay-based companion diagnostics for its schizophrenia candidates.
GEN

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Roche Taps Psynova to Develop Schizophrenia Companion Diagnostic

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Vetex Medical’s Thrombectomy Catheter Cleared by FDA

Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion

Abbott Gets FDA EUA for COVID-19 IgG Antibody Test

In $1.55 Billion Deal, Perrigo Sells Off Generic Drug Business

The Revised ICH E8: A Guide to New Clinical Trial Requirements